Business Wire

Cyolo Announces Cyolo PRO: A Hybrid Secure Remote Access Solution for OT Environments

4.3.2024 16:30:00 EET | Business Wire | Press release

Share

Cyolo, the access company for the digital enterprise, today announced the launch of Cyolo PRO (Privileged Remote Operations), a hybrid secure remote access solution for Operational Technology (OT). Developed specifically to enable safe operations of privileged users, Cyolo PRO is an advanced solution set to redefine Secure Remote Access (SRA) by shifting from managing access to managing operations. Aligning with the core principles of Remote Privileged Access Management (RPAM), Cyolo streamlines access processes providing a hybrid, infrastructure-agnostic solution with a low cost of change. Get Complimentary access to Gartner® report, Securing Remote Privileged Access Management Through RPAM Tools.

"As OT environments change, Cyolo PRO offers a comprehensive set of capabilities tailored to the unique, dynamic needs of organizations operating within these ecosystems. We have been attuned to the requirements emerging from the field, which has driven us to craft a secure, agile, and user-friendly tool,” said Almog Apirion, CEO & Co-founder at Cyolo. “This solution empowers organizations to seamlessly handle remote operations in their core units, without compromising productivity or security."

Cyolo PRO works across environments whether those are cloud-based, cloud-averse or offline. Key features of Cyolo PRO include:

  • VPN-less Connectivity with Zero Trust Principles: Cyolo PRO introduces VPN-less connectivity, eliminating the risks associated with network access while adhering to Zero Trust principles.
  • Identity Authentication and MFA for Legacy Apps: The solution ensures robust identity authentication, verifying the identity (instead of user) behind the access, even for legacy applications, enhancing overall security measures.
  • Granular Access and Actions Management: Cyolo PRO offers granular control over access and actions management using the principles of “least privilege”, providing organizations with a flexible and secure framework.
  • Massive Supervision Capabilities: The product includes extensive supervision features and Just in Time access, allowing organizations to monitor and manage remote access effectively.

“Our company has benefited a great deal from Cyolo’s platform,” said Gibson Mark, Senior Systems Administrator at Tata Chemicals. “We’re able to provide seamless remote access to our systems to both internal users and external users. The management overhead of these remote access connections has been greatly reduced. The ease of use of the remote access has been increased for third-party individuals and our internal employees. The adoption rates of these secure remote access methods have gone up substantially since we implemented Cyolo.”

Cyolo PRO is designed to answer the increasing security concerns and complexity around secure remote access in OT environments. Through its solution, Cyolo is empowering organizations with safe, secure and productive remote operations, even in the most demanding mission-critical settings. Its unique capabilities allow organizations to secure access to both internal and third-party users, operating online or offline and in hybrid, on-prem or cloud environments. This comprehensive suite also ensures industry compliance and guarantees uptime, safety and operational integrity.

“With Cyolo PRO’s features, tailored specifically for OT ecosystems, Cyolo is positioning itself as a market leader,” said Joe O’Donnell, Executive Vice President of Corporate Development at Cyolo. “The solution’s capability to seamlessly fit into existing architectures without extensive change management processes is critical in OT environments, as even the slightest change can yield significant consequences.”

Cyolo PRO is now available for enterprises across all critical industries, including manufacturing, oil & gas, utilities, pharmaceuticals, transportation and more. Consolidate your security stack and experience the power of seamless and secure operations across any application in any environment, from legacy infrastructure to cloud environments. Visit https://cyolo.io/ to learn more.

Gartner, Securing Remote Privileged Access Management Through RPAM Tools, Abhyuday Data, Felix Gaehtgens, Michael Kelley, 28 December 2023.
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

About Cyolo

Cyolo is a leading cybersecurity innovator dedicated to providing cutting-edge access solutions for all environments and deployment scenarios. With a focus on security, operational agility, and user experience, Cyolo is fostering a transition from merely enabling access to empowering operations, productivity, and compliance with its Cyolo PRO (Privileged Remote Operations) solution.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact
10Fold Communications
PR for Cyolo
cyolo@10fold.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye